Oncobiologics (ONS) Receives Average Recommendation of “Hold” from Brokerages

Shares of Oncobiologics (NASDAQ:ONS) have been given an average broker rating score of 3.00 (Hold) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation.

Zacks has also assigned Oncobiologics an industry rank of 150 out of 265 based on the ratings given to related companies.

A number of research analysts have recently issued reports on ONS shares. ValuEngine upgraded shares of Oncobiologics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Barclays downgraded shares of Oncobiologics from an “overweight” rating to an “equal weight” rating in a research report on Monday, January 29th.

Shares of Oncobiologics opened at $0.99 on Thursday, Marketbeat reports. The company has a current ratio of 0.22, a quick ratio of 0.49 and a debt-to-equity ratio of -0.10. Oncobiologics has a 1-year low of $0.78 and a 1-year high of $2.30.

Oncobiologics (NASDAQ:ONS) last announced its quarterly earnings data on Wednesday, February 14th. The company reported ($0.28) earnings per share for the quarter. The business had revenue of $0.77 million for the quarter.

About Oncobiologics

Oncobiologics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics in immunology and oncology disease areas. Its advanced product candidate is ONS-3010, an adalimumab biosimilar that is in a Phase 1 clinical trial, which targets the tumor necrosis factor alpha.

Get a free copy of the Zacks research report on Oncobiologics (ONS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply